Tilray Shares See Modest Bounce Amidst Cautious Market Sentiment

Tilray gains on low volume after a strategic US licensing deal with Carlsberg, despite posting a wider quarterly loss and trading below key technical levels.

Tilray Brands, Inc. saw its stock price advance by 4.9% on Tuesday, February 24, closing near $7.92. This uptick followed a prior session decline of 2.6%, which had pushed the share price down to $7.55. Market observers noted that both of these price movements occurred on below-average trading volume, suggesting a lack of strong conviction among both buyers and sellers.

Strategic Partnership with Carlsberg Provides Long-Term Focus

Looking beyond the daily price fluctuations, a significant strategic development was announced on February 18. The cannabis and beverage company entered into a multi-year licensing agreement with the Carlsberg Group. Effective January 1, 2027, Tilray will assume responsibility for the production, marketing, and distribution of Carlsberg’s portfolio—including the Carlsberg, Carlsberg Elephant, 1664, and Kronenbourg 1664 Blanc brands—within the United States.

This initial five-year contract includes provisions for an automatic five-year extension, contingent upon meeting specific performance benchmarks. The deal leverages Tilray’s position as the fourth-largest craft beer brewer in the U.S., with the company planning to utilize its existing infrastructure to expand Carlsberg's market share.

Financial Performance and Liquidity Position

The company’s most recent quarterly report, released on January 8 for the second quarter of fiscal 2026, presented a mixed picture. While revenue hit a record $217.5 million, surpassing analyst estimates of $211.15 million, earnings fell significantly short. Tilray reported a loss per share of $0.41, far worse than the anticipated loss of $0.14.

Key profitability metrics showed challenges, with a net margin of -251.69% and a return on equity of -6.35%. On a positive note, Tilray ended the quarter with a strong liquidity position, holding $291.6 million in cash and cash equivalents. The company's net cash exceeded its debt by approximately $30 million. A bright spot was the international medical cannabis business, which grew 36% year-over-year. Management reaffirmed its full-year fiscal 2026 adjusted EBITDA guidance of $62 to $72 million.

Trading Activity and Technical Perspective

The recent share price gain on February 24 was accompanied by trading volume of roughly 2.22 million shares. This figure sits about 50% below the stock’s average daily volume of 4.4 million shares. From a technical analysis standpoint, the equity continues to trade well below its key moving averages. The 50-day moving average rests at $8.95, and the 200-day average is at $11.12. Shares remain far from their 52-week high of $23.20. Tilray's current market capitalization is approximately $923 million.

Wall Street Maintains a Cautious Stance

Analyst sentiment toward Tilray remains predominantly neutral. The consensus rating on the stock is a "Hold." This breakdown includes one "Buy" recommendation, six "Hold" ratings, and one "Sell" recommendation. The average price target among analysts is $13.33.

Recent analyst actions include Roth MKM lowering its price target from $20 to $10 on January 20 while maintaining a Neutral rating. Canaccord Genuity Group initiated coverage with a Hold rating on January 27. Earlier, on February 11, Zacks Research upgraded its view on the shares from Strong Sell to Hold.

Path Forward

Investors are awaiting the next quarterly results, expected around April 7 or 8. Whether the stock can sustain its recent recovery will likely depend on broader sentiment within the cannabis sector and the company's continued execution of its growth strategy, which now includes the significant future Carlsberg partnership.